von Redaktion LCGC | Dez. 15, 2012
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z,Zhu G, Qian Z, Tang L, Zhan P,...
von Redaktion LCGC | Nov. 15, 2012
Genetic insight and therapeutic targets in squamous-cell lung cancer Sos ML, Thomas RK Journal: Oncogene, Vol 31, No 46, November 2012, doi: 10.1038/onc.2011.640Veröffentlichung: November...
von Redaktion LCGC | Okt. 15, 2012
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU,...
von Redaktion LCGC | Okt. 15, 2012
A framework for identification of actionable cancer genome dependencies in small cell lung cancer Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, Ullrich RT, Antonchick AP,...
von Redaktion LCGC | Sep. 15, 2012
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET Scheffler M, Kobe C, Zander T, Nogova L, Kahraman D, Thomas RK,...
